RNS Number : 4173U
Genedrive PLC
22 November 2019

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 48,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 21p per share.

Following these purchases, Dr Gilham is interested in 365,674 Ordinary Shares, 1.08% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

<table>
<tr><td>1.</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Ian Gilham</td></tr>
<tr><td>2.</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a.</td><td>Position/status</td><td>Non-Executive Chairman</td></tr>
<tr><td>a.</td><td>Initial notification /Amendment</td><td>Initial notification</td></tr>
<tr><td>3.</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>genedrive plc</td></tr>
<tr><td>b.</td><td>LEI</td><td>213800ZYODIRZ87Y4K14</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument
Identification code</td><td>Ordinary shares of 1.5 pence each

GB00B1VKB244</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>21p</td><td>48,000</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information</td><td>N/A</td></tr>
</table>

	· *Aggregated volume* · *Price*	
e.	*Date of the transaction*	*2019-11-22; UTC time*
f.	*Place of the transaction*	*London Stock Exchange, AIM*

For further details please contact:

genedrive plc +44 (0)161 989 0245

David Budd: CEO

Matthew Fowler: CFO

Peel Hunt LLP +44 (0)207 418 8900

James Steel

Oliver Jackson

Stanford Capital Partners Limited +44 (0)20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEALFAADPNFFF